Navigation Links
UH Case Medical Center publishes study on novel treatment for skin lymphoma

CLEVELAND: Promising findings on a novel combination treatment approach for a chronic type of skin lymphoma are being published today (embargoed for 4 pm) in JAMA's Archives of Dermatology by clinical researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine.

The article outlines findings from a first-of-its-kind study showing that O6-benzylguanine is successful in treating cutaneous T-Cell lymphoma by enhancing the efficacy of topical chemotherapy (carmustine).

"Current therapy for cutaneous T-Cell lymphoma is suboptimal and this new study shows that adding O6-benzylguanine to carmustine is more effective and less toxic to the skin, allowing for more optimal treatments," says Kevin Cooper, MD, Chairman of the Department of Dermatology at UH Case Medical Center and Case Western Reserve University School of Medicine. "This treatment essentially weakens the cancer cells to make the lymphoma more vulnerable to topical chemotherapy and has a lot of potential in alleviating patients' disease burden in this chronic and progressive disease."

Cutaneous T-cell lymphoma is a form of lymphoma which affects the skin and typically relapses and becomes increasingly challenging to treat. The new drug combination offers a potential new option for patients using skin-directed treatments, before the need to undergo systemic chemotherapy.

Clinical researchers at UH Case Medical Center and Case Western Reserve University have been investigating O6-benzylguanine over the past decade and were participants in the original research into its mechanism of action as a cancer treatment potentiator. This study, funded by National Cancer Institute grants to Case Western Reserve University in conjunction with Keryx Pharmaceuticals Inc., is the first to explore the drug's efficacy to intensify treatment for skin lymphoma.

When used alone, carmustine attaches to the DNA in the patient's cancer cells during the replication process, causing the cancer cells to die. Problems sometimes occur when an enzyme clips off the treatment from the DNA, allowing the cancer cells to replicate. O6-benzylguanine inhibits the enzyme from clipping off the carmustine from the DNA, so the drug can complete its mission and kill the cancer cells.

"By adding O6-benzylguanine, we can effectively lower the dosage of the topical treatment, carmustine, and render it less toxic on healthy cells but more effective at killing cancer cells," says Dr. Cooper. "This combination treatment has had excellent initial clinical results and we are following it up with additional ongoing studies."

Contact: Alicia Reale
University Hospitals Case Medical Center

Related medicine news :

1. Surgical robots to provide open-source platform for medical robotics research
2. CCNYs Robert Alfano wins first biomedical optics award
3. CareFirst BCBS and ACP offer new tool to advance development of patient-centered medical homes
4. Use of acupuncture in the US military highlighted in special issue of Medical Acupuncture
5. Lingua franca critical for electronic medical records and health information exchange
6. Self-affirmation may break down resistance to medical screening
7. Society of Interventional Radiology Foundation receives support from Siemens Medical
8. FDA Seeks to Get More Women Into Trials of Medical Devices
9. Experts Urge Limits on Medical Research on Chimpanzees
10. UW Medical Center granted magnet status for excellence in nursing care
11. Nations largest federation of biological and biomedical organizations welcomes 2 new members
Post Your Comments:
(Date:10/13/2015)... ... (PRWEB) October 13, ... hold its 2015 annual meeting and corresponding events Oct. 29-31 ... informational seminars; a luncheon featuring keynote speaker Air Force Gen. ... and the Community Heroes Award Night, which recognizes individuals and ...
(Date:10/13/2015)... ... 13, 2015 , ... The American Institutes for Research ( AIR ) developed ... students who have experienced sexual assault and other trauma. The toolkit, funded by the ... Violence Against Women Act's 21st anniversary. , AIR developed the Safe ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... "My friend's ... his fists into his infected cheeks," said an inventor from Platteville, Colo. "I came ... skin problems." , He developed the UNTOUCHABLE to prevent a child from rubbing or ...
(Date:10/13/2015)... ... October 13, 2015 , ... According to an article published ... that women who successfully lose weight with a bariatric procedure are much less likely ... The article notes that anywhere from 40 to 50 percent of all endometrial cancer ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... IBM software products, introduced a new company, RightSensorâ„¢ LLC, an Internet of Things ... capability. RightSensorâ„¢ provides a fully-managed approach for customers requiring sensor hardware for ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... DALLAS , Oct. 13, 2015   Generational ... privately-held, middle-market businesses, is pleased to announce the acquisition ... headquartered in Largo, Florida , by ... closed on September 11, 2015. ... . --> Florida . To ...
(Date:10/13/2015)... 13, 2015 According to the ... sponsored by Cardinal Health , achieving both ... diversified pharmacy revenue streams are vital to the ... NCPA Digest affirms that independent community ... in underserved inner city and rural areas," said ...
(Date:10/13/2015)... -- Data Science Automation (DSA), a system integration and automation engineering ... in the United Kingdom (UK) as ... . The decision to open the new office comes ... customers in the medical device industry throughout the UK. ... have had tremendous success over the last several years in ...
Breaking Medicine Technology: